Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Iovance Biotherapeutics (IOVA) Accumulated Depreciation & Amortization (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Accumulated Depreciation & Amortization for 9 consecutive years, with $48.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 35.4% to $48.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $48.8 million, a 35.4% increase, with the full-year FY2025 number at $48.8 million, up 35.4% from a year prior.
  • Accumulated Depreciation & Amortization was $48.8 million for Q4 2025 at Iovance Biotherapeutics, up from $45.3 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $48.8 million in Q4 2025 to a low of $19.4 million in Q1 2023.
  • A 3-year average of $36.1 million and a median of $39.1 million in 2024 define the central range for Accumulated Depreciation & Amortization.
  • Biggest YoY gain for Accumulated Depreciation & Amortization was 35.4% in 2025; the steepest drop was 35.4% in 2025.
  • Iovance Biotherapeutics' Accumulated Depreciation & Amortization stood at $25.2 million in 2023, then surged by 42.78% to $36.0 million in 2024, then soared by 35.4% to $48.8 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Accumulated Depreciation & Amortization are $48.8 million (Q4 2025), $45.3 million (Q3 2025), and $42.1 million (Q2 2025).